Puma Biotechnology, Inc. is a development-stage biopharmaceutical company dedicated to in-licensing and developing novel therapeutics for the treatment of cancer. Our strategy is to license technologies that have previously been tested in clinical trials, enabling us to obtain an initial indication of the drug's safety and biological activity in humans before committing capital to the drug's development.